<DOC>
	<DOCNO>NCT00656032</DOCNO>
	<brief_summary>The broad goal study understand mechanism Vitamin D receptor activation lead change insulin signal advanced uremia . We hypothesize 1,25-Dihydroxyvitamin D3 deficiency due advance chronic kidney disease lead insulin resistance administration vitamin D3 analog restore insulin sensitivity End Stage Renal Disease patient .</brief_summary>
	<brief_title>Vitamin D , Insulin Resistance Inflammation ESRD</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>CKD receive hemodialysis ≥ 3months Kt/V ≥ 1.2 ≥ 18 year age Medically stable AVF PTFE dialysis access No acute inflammatory disease within 4 week prior study On stable dose Paricalcitol 4 week prior study iPTH value 150 1500 within past 3 month Ca &lt; 10.5 PO4 &lt; 10 Pregnancy Intolerance study medication Severe , unstable , active , chronic inflammatory disease ( active infection , active connective tissue disorder , active cancer , HIV , liver disease ) Type 1 Diabetes mellitus Uncontrolled Type 2 Diabetes mellitus ( HbA1c &gt; 10 ) Hospitalization within 1 month prior study Malfunctioning arterialvenous vascular access ( recirculation and/or blood flow &lt; 250 ml/min ) Presence hemodialysis catheter Patients receive steroid and/or immunosuppressive agent ( &gt; 10 mg prednisone qd ) BMI &lt; 25 &gt; 45</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>insulin resistance</keyword>
	<keyword>end stage renal disease</keyword>
</DOC>